Factors Associated With Systemic Immune Activation Indices in a Global Primary Cardiovascular Disease Prevention Cohort of People With Human Immunodeficiency Virus on Antiretroviral Therapy

Imagem de Miniatura
Arquivos
art_LOOBY_Factors_Associated_With_Systemic_Immune_Activation_Indices_in_2022.PDF (1.69 MB)
Citações na Scopus
6
Tipo de produção
article
Data de publicação
2022
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
OXFORD UNIV PRESS INC
Autores
LOOBY, Sara E.
KANTOR, Amy
BURDO, Tricia H.
CURRIER, Judith S.
FICHTENBAUM, Carl J.
OVERTON, Edgar T.
ABERG, Judith A.
MALVESTUTTO, Carlos D.
BLOOMFIELD, Gerald S.
ERLANDSON, Kristine M.
Citação
CLINICAL INFECTIOUS DISEASES, v.75, n.8, p.1324-1333, 2022
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background. Among antiretroviral therapy (ART)-treated people living with human immunodeficiency virus (PLWH), persistent systemic immune activation contributes to atherogenesis atherosclerotic, cardiovascular disease (CVD) events, and mortality. Factors associated with key immune activation indices have not previously been characterized among a global primary CVD prevention cohort of PLWH. Methods. Leveraging baseline Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) data, we evaluated factors associated with soluble CD14 (sCD14) and oxidized low-density lipoprotein (oxLDL). Results. The primary analysis cohort included 4907 participants from 5 global-burden-of-disease regions (38% female, 48% Black, median age 50 years). In fully adjusted models for sCD14, female sex and White race (among those in high-income regions) were associated with higher sCD14 levels, while higher body mass index (BMI) and current use of nucleoside reverse transcriptase inhibitor + integrase strand transfer inhibitor ART were associated with lower sCD14 levels. In fully adjusted models for oxLDL, male sex, residence in high-income regions, White race (among those in high-income regions), and higher BMI were associated with higher oxLDL levels. In a subanalysis cohort of 1396 women with HIV, increased reproductive age was associated with higher sCD14 levels but not with higher oxLDL levels. Conclusions. Factors associated with sCD14 and oxLDL, 2 key indices of immune-mediated CVD risk, differ. Future studies will elucidate ways in which medications (eg, statins) and behavioral modifications influence sCD14 and oxLDL and the extent to which dampening of these markers mediates CVD-protective effects.
Palavras-chave
HIV, cardiovascular disease risk, immune activation markers, women, reproductive aging
URI
https://observatorio.fm.usp.br/handle/OPI/50552
Referências
  1. Abbafati C, 2020, LANCET, V396, P1204, DOI 10.1016/S0140-6736(20)30925-9
  2. Abelman Rebecca A, 2019, Curr Treat Options Cardiovasc Med, V21, P41, DOI 10.1007/s11936-019-0744-1
  3. Addo MM, 2014, J INFECT DIS, V209, pS86, DOI 10.1093/infdis/jiu175
  4. Bogorodskaya MM., 2021, CROI
  5. Cejtin HE, 2018, J WOMENS HEALTH, V27, P1441, DOI 10.1089/jwh.2018.7046
  6. Fichtenbaum CJ, 2020, J INFECT DIS, V222, pS8, DOI 10.1093/infdis/jiaa259
  7. Foldyna B, 2018, JAIDS-J ACQ IMM DEF, V78, P421, DOI 10.1097/QAI.0000000000001686
  8. Frazier EL, 2019, CLIN INFECT DIS, V69, P2091, DOI 10.1093/cid/ciz126
  9. Gal-Oz ST, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12348-6
  10. Grinspoon SK, 2020, J INFECT DIS, V222, pS1, DOI 10.1093/infdis/jiaa098
  11. Grinspoon SK, 2019, AM HEART J, V212, P23, DOI 10.1016/j.ahj.2018.12.016
  12. Hileman CO, 2015, J INFECT DIS, V212, P345, DOI 10.1093/infdis/jiv004
  13. Hoffmann U, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.14923
  14. Hsue PY, 2012, J INFECT DIS, V205, pS375, DOI 10.1093/infdis/jis200
  15. Hunt PW, 2016, J INFECT DIS, V214, pS44, DOI 10.1093/infdis/jiw275
  16. Jamialahmadi T, 2021, MEDIAT INFLAMM, V2021, DOI 10.1155/2021/9661752
  17. Kelesidis T, 2012, J INFECT DIS, V206, P1558, DOI 10.1093/infdis/jis545
  18. Koenig W, 2011, CLIN CHEM, V57, P1196, DOI 10.1373/clinchem.2011.165134
  19. Koethe JR, 2013, AIDS RES HUM RETROV, V29, P1019, DOI [10.1089/aid.2013.0016, 10.1089/AID.2013.0016]
  20. Lake JE, 2014, HIV MED, V15, P431, DOI 10.1111/hiv.12128
  21. Lederman MM, 2013, ADV IMMUNOL, V119, P51, DOI 10.1016/B978-0-12-407707-2.00002-3
  22. Lo J, 2010, AIDS, V24, P243, DOI 10.1097/QAD.0b013e328333ea9e
  23. Looby SE, 2016, AIDS, V30, P383, DOI 10.1097/QAD.0000000000000902
  24. Naghavi M, 2017, LANCET, V390, P1151, DOI 10.1016/S0140-6736(17)32152-9
  25. Nou E, 2016, AIDS, V30, P583, DOI 10.1097/QAD.0000000000000946
  26. Peters BA, 2022, J INFECT DIS, V225, P295, DOI 10.1093/infdis/jiab341
  27. Post WS, 2014, ANN INTERN MED, V160, P458, DOI 10.7326/M13-1754
  28. Raghavan A, 2017, CURR HIV-AIDS REP, V14, P220, DOI 10.1007/s11904-017-0366-8
  29. Reiner AP, 2013, ARTERIOSCL THROM VAS, V33, P158, DOI 10.1161/ATVBAHA.112.300421
  30. Rhoads JP, 2018, CRIT REV IMMUNOL, V38, P333, DOI 10.1615/CritRevImmunol.2018026483
  31. Roth GA, 2020, J AM COLL CARDIOL, V76, P2982, DOI 10.1016/j.jacc.2020.11.010
  32. Sandler NG, 2011, J INFECT DIS, V203, P780, DOI 10.1093/infdis/jiq118
  33. Schnittman SB-EG., 2021, SEX MODIFIES ASS INF
  34. Scully EP, 2018, CURR HIV-AIDS REP, V15, P136, DOI 10.1007/s11904-018-0383-2
  35. Shieh A, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.134092
  36. Shive CL, 2015, AIDS, V29, P1263, DOI 10.1097/QAD.0000000000000735
  37. Toribio M, 2017, AIDS, V31, P797, DOI 10.1097/QAD.0000000000001427
  38. Weinbrenner T, 2006, AM J CLIN NUTR, V83, P30
  39. World Health Organization, WAIST CIRCUMFERENCE
  40. Zanni MV, 2020, J INFECT DIS, V222, pS20, DOI 10.1093/infdis/jiaa214
  41. Zanni MV, 2017, J INFECT DIS, V215, P1264, DOI 10.1093/infdis/jix095
  42. Zidar DA, 2015, JAIDS-J ACQ IMM DEF, V69, P154, DOI 10.1097/QAI.0000000000000566

Coleções
Artigos e Materiais de Revistas Científicas - FM/MIP
Artigos e Materiais de Revistas Científicas - LIM/60
Artigos e Materiais de Revistas Científicas - ODS/03
Artigos e Materiais de Revistas Científicas - ODS/05